News + Filings Transactions
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
|
BRYNJELSEN SEAN
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
09/23/2022 |
4
| BRYNJELSEN SEAN (CEO) has filed a Form 4 on Eton Pharmaceuticals, Inc.
Txns:
| Bought 10,000 shares
@ $2.1042, valued at
$21k
|
|
07/18/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/28/2022 |
4
| BRYNJELSEN SEAN (President & CEO) has filed a Form 4 on Eton Pharmaceuticals, Inc.
Txns:
| Granted 416,500 options to buy
@ $3.78, valued at
$1.6M
|
|
08/20/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/03/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/16/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/04/2020 |
SC 13G/A
| BRYNJELSEN SEAN reports a 7.6% stake in Eton Pharmaceuticals, Inc. |
08/13/2019 |
4
| BRYNJELSEN SEAN (President & CEO) has filed a Form 4 on Eton Pharmaceuticals, Inc.
Txns:
| Bought 5,000 shares
@ $6.15, valued at
$30.8k
|
|
05/22/2019 |
4
| BRYNJELSEN SEAN (President & CEO) has filed a Form 4 on Eton Pharmaceuticals, Inc.
Txns:
| Bought 1,400 shares
@ $7.782, valued at
$10.9k
Bought 8,600 shares
@ $7.9571, valued at
$68.4k
|
|
03/08/2019 |
4
| BRYNJELSEN SEAN (President & CEO) has filed a Form 4 on Eton Pharmaceuticals, Inc.
Txns:
| Granted 250,000 options to buy
@ $7.31, valued at
$1.8M
|
|
02/11/2019 |
SC 13G
| BRYNJELSEN SEAN reports a 6.6% stake in Eton Pharmaceuticals, Inc. |
11/15/2018 |
4
| BRYNJELSEN SEAN (President & CEO) has filed a Form 4 on Eton Pharmaceuticals, Inc.
Txns:
| Converted 24,940 shares
@ $0 Bought 10,000 shares
@ $6, valued at
$60k
Converted 23,000 convertible preferred
@ $0 |
|
11/13/2018 |
3
| BRYNJELSEN SEAN (President & CEO) has filed a Form 3 on Eton Pharmaceuticals, Inc. |
08/31/2016 |
4
| BRYNJELSEN SEAN (EVP, Business Development) has filed a Form 4 on Sagent Pharmaceuticals, Inc.
Txns:
| Disposed/sold 9,844 shares
@ $21.75, valued at
$214.1k
Disposed/sold 21,016 options to buy
@ $12.19, valued at
$256.2k
|
|
04/06/2016 |
3
| BRYNJELSEN SEAN (EVP, Business Development) has filed a Form 3 on Sagent Pharmaceuticals, Inc. |
04/06/2016 |
4
| BRYNJELSEN SEAN (EVP, Business Development) has filed a Form 4 on Sagent Pharmaceuticals, Inc.
Txns:
| Granted 9,844 shares
@ $0 Granted 21,016 options to buy
@ $12.19, valued at
$256.2k
|
|
|
|